Clinical Trials Browser

Phase 3 × INDUSTRY × Abiraterone Acetate × Clear all

NCT02257736 2026-03-19

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Prostatic Neoplasms

NCT03748641 2026-03-16

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Phase 3 Active not recruiting

110 enrolled 12 charts

Metastatic Castration-resistant Prostate Cancer

NCT06136624 2026-03-11

OMAHA-003

Phase 3 Recruiting

Prostate Cancer Metastatic

NCT06136650 2026-03-09

MK-5684-004

Phase 3 Recruiting

Prostatic Neoplasms

NCT07213674 2026-02-27

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT06120491 2026-01-21

EvoPAR-PR01

Phase 3 Recruiting

Prostatic Neoplasms

NCT04493853 2026-01-20

CAPItello-281

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT00887198 2025-02-04

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Completed

1,088 enrolled 14 charts

Prostatic Neoplasms

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Phase 3 Completed

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04844749 2024-02-05

VERACITY

Phase 3 Terminated

Prostatic Neoplasms, Castration-Resistant

NCT04887506 2024-01-16

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Phase 3 Completed

107 enrolled 20 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT01517802 2022-05-10

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Phase 3 Completed

32 enrolled 7 charts

Breast Neoplasms

NCT01591122 2020-01-21

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT04056754 2019-08-14

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Phase 3 Completed

Metastatic Castration Resistant Prostate Cancer

NCT01695135 2019-07-18

A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

Phase 3 Completed

214 enrolled 16 charts

Prostatic Neoplasms